Baird lowered the firm’s price target on Karyopharm (KPTI) to $21 from $25 and keeps an Outperform rating on the shares. The firm updated its model to reflect its strategic financing allowing a cash runway through its Phase 3 MF data in March 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KPTI:
- Karyopharm Therapeutics: Strategic Financing Extends Cash Runway Amid Cautious Hold Rating
- Karyopharm price target lowered to $6 from $8 at Leerink
- Morning Movers: AST SpaceMobile jumps after direct-to-cellular pact with Verizon
- Karyopharm Secures $100M Financing for Clinical Trials
- Karyopharm announces $100M strategic financing plan